ArticleJournal of clinical microbiology2022
Core Genome Multilocus Sequence Typing Scheme for Improved Characterization and Epidemiological Surveillance of Pathogenic Brucella.
Article in Journal of clinical microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Brucellosis in Southeast Asia: A Systematic Review of Epidemiological Evidence, Surveillance Gaps, and cgMLST-Based Insights Into Genetic Relatedness.Transboundary and emerging diseases · 2026Pooled it
- Complete genome sequences of threeMicrobiology resource announcements · 2026Article
- Genomic outbreak investigation of biosafety-level-3 pathogens using nanopore sequencing.Microbial genomics · 2026Article
- A standardized core genome multilocus sequence typing and life identification number barcoding framework for globalMicrobial genomics · 2026Article
- Laboratory-AcquiredPathogens (Basel, Switzerland) · 2026Article
- Impact of inactivation methods on biosafety and antigen reactivity of Brucella melitensis from the perspective of Astral-DIA proteomics based on antibody immunoprecipitation mass spectrometry.PLoS neglected tropical diseases · 2026Article
- Genomic analysis of Brucella Ovis in Italy reveals high genetic diversity and a novel lineage.BMC veterinary research · 2026Article
- Towards Integrated Surveillance of Marine Brucellosis: Diagnostic and Phylogenetic Assessment ofTransboundary and emerging diseases · 2026Article
- Identification and Genome Phylogenetic Analysis of ThreeTransboundary and emerging diseases · 2026Article
- Isolation of Brucella suis from cattle in India: whole genome analysis unravels potential for zoonotic transmission.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Genomic and spatial heterogeneity of Brucella melitensis underscores latent brucellosis risks in non-endemic zones in Southwest China.Communications biology · 2025Article
- Investigation of Possible Intraoperative Transmission of Brucella melitensis, Slovenia.Emerging infectious diseases · 2025Article
- Article
- Investigation of genomic island 2 deciphers the evolution of a genus Brucella.Scientific reports · 2025Article
- Genomic insights intoMicrobiology spectrum · 2025Article
- Genomic analysis of Brucella melitensis isolates recovered from humans in south Tunisia over 35 years between 1988 and 2022.BMC microbiology · 2025Article
- Genomic epidemiology ofFrontiers in veterinary science · 2025Article
- Phylogenetic evidence for nationwide expansionFrontiers in cellular and infection microbiology · 2025Article
- Genomic epidemiology of a novelFrontiers in cellular and infection microbiology · 2025Article
- Detection and Molecular Diversity ofPathogens (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 5 countries.
Funding
Abstract
Brucellosis poses a significant burden to human and animal health worldwide. Robust and harmonized molecular epidemiological approaches and population studies that include routine disease screening are needed to efficiently track the origin and spread of Brucella strains. Core genome multilocus sequence typing (cgMLST) is a powerful genotyping system commonly used to delineate pathogen transmission routes for disease surveillance and control. Except for Brucella melitensis, cgMLST schemes for Brucella species are currently not established. Here, we describe a novel cgMLST scheme that covers multiple Brucella species. We first determined the phylogenetic breadth of the genus using 612 Brucella genomes. We selected 1,764 genes that were particularly well conserved and typeable in at least 98% of these genomes. We tested the new scheme on 600 genomes and found high agreement with the whole-genome-based single nucleotide polymorphism (SNP) analysis. Next, we applied the scheme to reanalyze the genome of Brucella strains from epidemiologically linked outbreaks. We demonstrated the applicability of the new scheme for high-resolution typing required in outbreak investigations as previously reported with whole-genome SNP methods. We also used the novel scheme to define the global population structure of the genus using 1,322 Brucella genomes. Finally, we demonstrated the possibility of tracing distribution of Brucella strains by performing cluster analysis of cgMLST profiles and found nearly identical cgMLST profiles in different countries. Our results show that sequencing depth of more than 40-fold is optimal for allele calling with this scheme. In summary, this study describes a novel Brucella-wide cgMLST scheme that is applicable in Brucella molecular epidemiology and helps in accurately tracking and thus controlling the sources of infection. The scheme is publicly accessible and should represent a valuable resource for laboratories with limited computational resources and bioinformatics expertise.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.